Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.22 USD | -2.18% | -7.63% | -17.95% |
05-10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
05-08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.95% | 1.14B | |
+48.67% | 56.69B | |
-2.76% | 41B | |
+38.05% | 38.11B | |
-11.22% | 26.89B | |
+9.25% | 25.59B | |
-23.10% | 18.59B | |
+1.88% | 12.39B | |
+26.43% | 11.99B | |
+21.74% | 11.88B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Mirum Pharmaceuticals, Inc. announced that it has received $10 million in funding from Oberland Capital Management LLC and other investors